Selective phosphodiesterase 3 inhibitor olprinone attenuates meconium-induced oxidative lung injury

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 3, 2012, Pages 216-222

  Mokra, Daniela ^a   Drgova, Anna ^a   Pullmann, Rudolf ^a   Calkovska, Andrea ^a  

^a Martinska Fakultna Nemocnica   (Slovakia)

Author keywords

Lung injury; Meconium; Olprinone; Oxidation; Phosphodiesterase inhibitor

Indexed keywords

ALKADIENE; CYTOCHROME C OXIDASE; DITYROSINE; LOPRINONE; LYSINE; SODIUM CHLORIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTERIAL BLOOD; ARTICLE; BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRY WEIGHT; ENZYME ACTIVITY; LEUKOCYTE COUNT; LIPID PEROXIDATION; LUNG EDEMA; LUNG HOMOGENATE; LUNG INJURY; LUNG LAVAGE; LUNG PARENCHYMA; LUNG VENTILATION; LUNG WEIGHT; MECONIUM; MITOCHONDRION; NONHUMAN; OXIDATION KINETICS; PNEUMONIA; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; EDEMA; HUMANS; IMIDAZOLES; INFANT, NEWBORN; INFLAMMATION; LEUKOCYTE COUNT; LUNG INJURY; MECONIUM; MITOCHONDRIA; OXIDATIVE STRESS; PHOSPHODIESTERASE 3 INHIBITORS; PYRIDONES; RABBITS;

EID: 84860601367     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.02.007     Document Type: Article

References (36)

1. Mokra D., Mokry J. Meconium aspiration syndrome: from pathomechanisms to treatment 2010, Nova Science Publishers, New York, p. 130. 1st ed.
2. de Beaufort A.J., Bakker A.C., van Tol M.J.D., Poorthius B.J., Schrama A.J., Berger H.M. Meconium is a source of pro-inflammatory substances and can induce cytokine production in cultured A549 epithelial cells. Pediatr Res 2003, 54:491-495.
3. Soukka H.R., Ahotupa M., Ruutu M., Kääpä P.O. Meconium stimulates neutrophil oxidative burst. Am J Perinatol 2002, 19:279-284.
4. Mokry J., Mokra D., Antosova M., Bulikova J., Calkovska A., Nosalova G. Dexamethasone alleviates meconium-induced airway hyperresponsiveness and lung inflammation in rabbits. Pediatr Pulmonol 2006, 41:55-60.
5. Craig S., Lopez A., Hoskin D., Markham F. Meconium inhibits phagocytosis and stimulates respiratory burst in alveolar macrophages. Pediatr Res 2005, 57:813-818.
6. Mokra D., Mokry J., Tatarkova Z., Redfors B., Petraskova M., Calkovska A. Aminophylline treatment in meconium-induced acute lung injury in a rabbit model. J Physiol Pharmacol 2007, 58(Suppl. 5):399-407.
7. Currie G.P., Butler C.A., Anderson W.J., Skinner C. Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment. Br J Clin Pharmacol 2008, 65:803-810.
8. de Visser Y.P., Walther F.J., Laghmani E.H., van Wijngaarden S., Nieuwland K., Wagenaar G.T. Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury. Eur Respir J 2008, 31:633-644.
9. Koike T., Nadeen Qutab M., Tsuchida M., Takekubo M., Saito M., Hayashi J. Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect. Pulm Pharmacol Ther 2008, 21(1):166-171.
10. Mokry J., Mokra D., Nosalova G., Beharkova M., Feherova Z. Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity. J Physiol Pharmacol 2008, 59(Suppl. 6):473-482.
11. Mokry J. PDE inhibitors in airway diseases. Pediatria (Bratisl) 2010, 5:101-107.
12. Shekerdemian L.S., Ravn H.B., Penny D.J. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002, 165:1098-1102.
13. Bassler D., Choong K., McNamara P., Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 2006, 89:1-5.
14. Mizushige K., Ueda T., Yukiiri K., Suzuki H. Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev 2002, 20:163-174.
15. Myou S., Fujimura M., Kamio Y., Hirose T., Kita T., Tachibana H., et al. Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients. Br J Clin Pharmacol 2003, 55:341-346.
16. Ueda T., Mizushige K. The effects of olprinone, a phosphodiesterase 3 inhibitor, on systemic and cerebral circulation. Curr Vasc Pharmacol 2006, 4:1-7.
17. Mokry J., Nosalova G. The influence of the PDE inhibitors on cough reflex in guinea pigs. Bratisl Lek Listy 2011, 112:131-135.
18. Nakamura T., Suzuki S., Ushiyama C., Shimada N., Koide H. Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure. Acta Cardiol 2002, 57:19-21.
19. Mikawa K., Akamatsu H., Nishina K., Shiga M., Maekawa N., Obara H., et al. The effect of phosphodiesterase III inhibitors on human neutrophil function. Crit Care Med 2000, 28:1001-1005.
20. Essayan D.M. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001, 108:671-680.
21. Giembycz M.A. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005, 5:238-244.
22. Yamaura K., Akiyoshi K., Irita K., Taniyama T., Takahashi S. Effects of olprinone, a new phosphodiesterase inhibitor, on gastric intramucosal acidosis and systemic inflammatory responses following hypothermic cardiopulmonary bypass. Acta Anaesthesiol Scand 2001, 45:427-434.
23. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
24. Giulivi C., Davies K.J. Dityrosine: a marker for oxidatively modified proteins and selective proteolysis. Methods Enzymol 1994, 233:363-371.
25. Dousset N., Ferretti G., Taus M., Valdiguie P., Curatola G. Fluorescence analysis of lipoprotein peroxidation. Methods Enzymol 1994, 233:459-469.
26. Das D.K. Cellular, biochemical and molecular aspects of reperfusion injury. Ann NY Acad Sci 1994, 723:118-124.
27. Braughler J.M., Duncan L.A., Chase R.L. The involment of iron in lipid peroxidation. importance of ferric to ferrous ration in initiation. J Biol Chem 1986, 261:10282-10289.
28. Hu M.L. Measurement of protein thiol groups and gluthatione in plasma. Methods Enzymol 1994, 233:380-385.
29. Capaldi R.A., Marusich M.F., Taanman J.W. Mammalian cytochrome c oxidase: characterization of enzyme and immunological detection of subunits in tissue extracts and whole cell. Methods Enzymol 1995, 260:117-132.
30. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008, 155:308-315.
31. Ferreira P.J., Bunch T.J., Albertine K.H., Carlton D.P. Circulating neutrophil concentration and respiratory distress in premature infants. J Pediatr 2000, 136:466-472.
32. Brown D.M., Hutchison L., Donaldson K., MacKenzie S.J., Dick C.A., Stone V. The effect of oxidative stress on macrophages and lung epithelial cells: the role of phosphodiesterases 1 and 4. Toxicol Lett 2007, 168:1-6.
33. Kuniyoshi T., Kakihana Y., Isowaki S., Nagata E., Tobo K., Kaminosono T., et al. Effects of olprinone on hepatosplanchnic circulation and mitochondrial oxidation in a porcine model of endotoxemia. J Anesth 2005, 19:295-301.
34. Aaltonen M., Soukka H., Halkola L., Jalonen J., Holopainen I.E., Kääpä P.O. Meconium aspiration induces oxidative injury in the hippocampus of newborn piglets. Early Hum Dev 2005, 81:439-447.
35. Mizutani A., Murakami K., Okajima K., Kira S., Mizutani S., Kudo K., et al. Olprinone reduces ischemia/reperfusion-induced acute renal injury in rats through enhancement of cAMP. Shock 2005, 24:281-287.
36. Kooistra M.R., Corada M., Dejana E., Bos J.L. Epac1 regulates integrity of endothelial cell junctions through VE-cadherin. FEBS Lett 2005, 579:4966-4972.